Artelo Biosciences
ARTL
8 hedge funds and large institutions have $121K invested in Artelo Biosciences in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, reducing their positions, and 4 closing their positions.
0.06% more ownership
Funds ownership: 1.56% → 1.63% (+0.06%)
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
20% less capital invested
Capital invested by funds: $152K → $121K (-$31.1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$86.4K |
| 2 |
Two Sigma Investments
New York
|
+$53.4K |
| 3 |
VF
Virtu Financial
New York
|
+$43.6K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$29.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$78.9K |
| 2 |
Morgan Stanley
New York
|
-$5.05K |
| 3 |
Citigroup
New York
|
-$2.19K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$138 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $41K | +$86.4K | +11,137 | +15,910% |
|
|
2
Two Sigma Investments
New York
| $25.2K | +$53.4K | +6,890 | New |
|
|
VF
3
Virtu Financial
New York
| $21K | +$43.6K | +5,622 | New |
|
4
Vanguard Group
Malvern,
Pennsylvania
| $17.1K | – | – | – |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| $13.9K | +$29.5K | +3,799 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $2.32K | +$4.92K | +634 | New |
|
7
Bank of America
Charlotte,
North Carolina
| $21 | +$16 | +2 | +50% |
|
|
RIL
8
Rothschild Investment LLC
Chicago,
Illinois
| $2 | – | – | – |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $1 | – | – | – |
|
|
DS
10
DRW Securities
Chicago,
Illinois
| – | -$78.9K | -5,728 | Closed |
|
|
11
Morgan Stanley
New York
| – | -$5.05K | -367 | Closed |
|
|
12
Citigroup
New York
| – | -$2.19K | -159 | Closed |
|
|
13
Fidelity Investments
Boston,
Massachusetts
| – | -$138 | -10 | Closed |
|
ARTL Hedge Fund Activity: Q4 2025 in Review
8 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q4 2025, worth a combined $121K — down 20% from $152K a quarter earlier.
Fund positioning in ARTL was balanced in Q4 2025: 4 funds opened new positions, 4 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $86.4K. The largest seller was DRW Securities, exiting entirely with an estimated $78.9K sold.
- 8 institutional investors held Artelo Biosciences (ARTL) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $121K of Artelo Biosciences stock for Q4 2025, down 20% quarter-over-quarter.
- 4 funds opened new Artelo Biosciences positions in Q4 2025 and 4 closed out, a net change of 0 holders.
- The largest Artelo Biosciences buyer in Q4 2025 was UBS Group, an estimated $86.4K added.
- The largest Artelo Biosciences seller in Q4 2025 was DRW Securities, an estimated $78.9K sold.
Based on aggregated 13F filings for Q4 2025.